Lurbinectedin is a drug that is used for the treatment of small cell lung cancer (SCLC) and is not approved for use in pregnant animals. According to the FDA label for Lurbinectedin, it is classified as a Pregnancy Category D drug, which means that there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks [2]. The label also states that Lurbinectedin can cause fetal harm when administered to a pregnant woman, and that women of reproductive potential should use effective contraception during treatment with Lurbinectedin and for at least 6 months after the last dose [2].

There is no specific information available on the safety of Lurbinectedin for pregnant animals. However, according to Drug Patent Watch, there are no patents listed for Lurbinectedin that mention the use of the drug in pregnant animals [1]. It is important to note that animal studies are often conducted before a drug is approved for human use, but they are not always predictive of how a drug will affect humans or other animals.

In conclusion, Lurbinectedin is not approved for use in pregnant animals and is classified as a Pregnancy Category D drug in humans. Women of reproductive potential should use effective contraception during treatment with Lurbinectedin and for at least 6 months after the last dose. There is no specific information available on the safety of Lurbinectedin for pregnant animals.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] https://reference.medscape.com/drug/zepzelca-lurbinectedin-4000075